External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>We think Yidu’s FY23E (Mar-YE) earnings has been heavily impacted by COVID resurgence in CY4Q22 in China and that healthcare institutions have slowed down the digitalization pace.</li><li>In FY23E, we expect Yidu’s revenue to be down 22% YoY (-5.5% YoY in FY1H23) but net loss could narrow to RMB460mn (vs. - RMB762mn in FY22) on better opex control.</li><li>Mgmt. guided to achieve adj. EBITDA breakeven in FY24E. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We think Yidu’s FY23E (Mar-YE) earnings has been heavily impacted by COVID resurgence in CY4Q22 in China and that healthcare institutions have slowed down the digitalization pace.In FY23E, we expect Yidu’s revenue to be down 22% YoY (-5.5% YoY in FY1H23) but net loss could narrow to RMB460mn (vs. - RMB762mn in FY22) on better opex control.Mgmt. guided to achieve adj. EBITDA breakeven in FY24E. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Yidu Tech (2158 HK) – Eyes on post-COVID business recovery

China

Yidu Tech is an investment holding company that provides healthcare solutions built on big data and artificial intelligence (AI) technologies. It focuses on AI-driven healthcare transformation, developing professional, efficient, precise, and accessible AI products and solutions for the healthcare industry. The company was founded in 2014 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yidu Tech (2158 HK) – Eyes on post-COVID business recovery

We think Yidu’s FY23E (Mar-YE) earnings has been heavily impacted by COVID resurgence in CY4Q22 in China and that healthcare institutions have...

CMB International